Background. Studies show that women with low vitamin D levels have an increased risk of breast cancer (BC) incidence and mortality, but there is a lack of research examining vitamin D levels and prognostic variables in BC patients. The aim of this study is to examine 25-OH vitamin D levels between BC cases and controls and by prognostic indicators among BC cases. Methods. 25-OH vitamin D levels were collected from 194 women who underwent BC surgery and 194 cancerfree (CF) controls at the University of Rochester between January 2009 and October 2010. Mean 25-OH vitamin D levels and odds ratios (OR) were calculated by case/control status for the overall cohort and by prognostic indicators (invasiveness, ER status, triple-negative status, Oncotype DX score, molecular phenotype) for BC cases. Results. BC cases had significantly lower 25-OH vitamin D levels than CF controls (BC: 32.7 ng/mL vs. CF: 37.4 ng/mL; P = .02). In case-series analyses, women with suboptimal 25-OH vitamin D concentrations (\32 ng/mL) had significantly higher odds of having ER-(OR = 2.59, 95% confidence interval [95% CI] = 1.08-6.23) and triple-negative cancer (OR = 3.15, 95% CI = 1.05-9.49) than those with optimal 25-OH D concentrations. Women with basallike phenotype had lower 25-OH vitamin D levels than women luminal A phenotype (basal-like: 24.2 ng/mL vs. luminal A: 32.8 ng/mL; P = 0.04). 1 In these tissues, calcitriol binds to and activates the vitamin D receptor (VDR), where it acts as a transcription factor to modulate gene expression affecting cell cycle proliferation, cell cycle arrest, induction of differentiation, and activation of apoptosis.
Vitamin D, obtained primarily through sun exposure, diet, and dietary supplements, plays a role in bone metabolism, calcium absorption, and other physiologic processes. The circulating form of vitamin D, 25-hydroxycholecalciferol (25-OH vitamin D; calcidiol), is formed by hydroxylation of vitamin D 3 . 25-OH vitamin D is further hydroxylated to the active form, calcitriol (1,25-dihydroxycholecalciferol) in the renal tubules and in many other sites, including the epithelial cells of mammary tissue. 1 In these tissues, calcitriol binds to and activates the vitamin D receptor (VDR), where it acts as a transcription factor to modulate gene expression affecting cell cycle proliferation, cell cycle arrest, induction of differentiation, and activation of apoptosis.
Because of the effects of vitamin D on various cell cycle pathways, its role in breast cancer (BC) incidence and progression has been thoroughly investigated. While the literature is inconsistent, numerous studies have shown that adequate vitamin D levels reduce the risk of BC and improve survival after diagnosis. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Patients with high plasma levels of vitamin D (both 25-OH vitamin D and calcitriol) have up to a 45% reduction in the risk of BC compared with those with low vitamin D levels. 11, 12 Additionally, sufficient vitamin D levels predict both distant disease-free and overall survival in women with breast cancer. 2 These positive effects of vitamin D on BC incidence and survival may be related to its antiproliferative and immunoregulatory effects.
Less is known about the effects of vitamin D on various prognostic indicators in patients with breast cancer. An understanding of how vitamin D affects these prognostic indicators may elucidate mechanisms by which vitamin D influences BC progression and survival. Vitamin D insufficiency is a common clinical problem in these patients; our research group and others have shown that vitamin D levels are frequently insufficient or deficient in BC patients (66% deficient) and survivors (7.2% deficient; 69.4% insufficient). 6, 13 Moreover, non-white women have lower vitamin D levels and are at greater risk of breast cancer, but we do not yet understand why? 14, 15 An understanding of the relationship between vitamin D and BC prognostic indicators-both demographic variables and tumor characteristics-will help clarify disease pathogenesis and possibly lead to identification of those patients for whom supplementation will improve survival. Classification of BC by histologic characteristics and gene expression markers (e.g., Ki-67 cellular proliferation, estrogen [ER] and progesterone [PR] receptor status, human epidermal growth factor 2 [HER2/neu]) has led to improved predictability of disease behavior in recent years. Given the positive effects of vitamin D on incidence and survival from breast cancer, further understanding of the relationship of vitamin D and these prognostic factors will lead to understanding vitamin D's effects in relation to hormones and cell cycle regulation. The aim of this study is to describe the associations between 25-OH vitamin D levels at the time of diagnosis with many of these demographic, pathological, and genetic characteristics of breast cancers.
METHODS

Study Population
A total of 194 women who were diagnosed with stage 0-III BC had their 25-OH vitamin D levels measured and underwent surgery at the James P. Wilmot Cancer Center in the University of Rochester Medical Center between January 6, 2009, and November 9, 2010, were included in this study. Eligibility criteria included women with histologically confirmed primary, incident, breast cancer, with no prior cancer history except nonmelanoma skin cancer. A blood specimen taken a mean of 30.1 days prior to surgery was used to determine the total 25-OH vitamin D level (the sum of 25-OH vitamin D 2 and 25-OH vitamin D 3 ). Controls were selected from 37,337 women between the ages of 40 and 70 who had their total 25-OH vitamin D level measured for the first time between January 2009 and October 2010. Individuals currently under treatment for cancer at any site or previously diagnosed with cancer (determined by ICD-9 coding) were not eligible for this study. Controls were matched to cases at a 1:1 ratio on age (5-year category) and date (month and year) of blood collection. 
Clinical Data and Prognostic Characteristics
Clinical information that included age, menopausal status (postmenopausal defined as 12 consecutive months of amenorrhea or bilateral oophorectomy), race (white or non-white), and family history of BC (yes/no) was obtained from medical records. Tumor pathology was performed by the Department of Surgical Pathology, and the relevant data were acquired from the corresponding reports. Prognostic indicators included clinical stage (0, I, II, or III), tumor size, lymph node involvement, estrogen receptor (ER) status (?/-), progesterone receptor (PR) status (?/-), human epidermal growth factor receptor 2 (HER2) status (?/-), triple-negative status (ER-, PR-, and HER2-), molecular phenotype (basal-like, Luminal A, Luminal B, and HER2), Ki-67 expression, and Oncotype DX score. 16, 17 Data are missing for a significant number of participants for the variables Ki-67 expression (n = 68) and Oncotype DX score (n = 39), because these tests were not performed as part of the routine pathological examination.
Statistical Analysis
There were two distinct types of statistical analyses used in this study: case-control analyses that used noncancer controls as a referent group and case-only analyses that used the better prognostic indicator (ER?, PR?, non-triple negative tumors, noninvasive tumors, Ki-67 expression B 10, Oncotype DX score B 18, Luminal A/B gene expression, and no family history of breast cancer) as the referent group. First, serum 25-OH vitamin D levels were compared using a generalized linear model (ANCOVA) that controlled for age, race, date of blood collection, and laboratory used for vitamin D testing. Adjusted least square means and corresponding P values of 25-OH vitamin D levels were calculated separately by case-control status, and by clinical variables and tumor characteristics for the case-only analyses.
In addition to continuous 25-OH vitamin D levels, categorical designations were used for vitamin D (optimal C 32 ng/mL; suboptimal \ 32 ng/mL; insufficient = 20-31 ng/ mL; deficient \ 20 ng/mL). Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI) for case-control status and prognostic indicators (case-only analysis) by categorical 25-OH vitamin D levels. Statistical trends were determined by entering continuous 25-OH vitamin D values into logistic regression models for case-control status and all prognostic indicators. All logistic regression models were adjusted for age, race, date of blood collection, and laboratory used for vitamin D testing. When outcomes had more than two levels, the outcome was transformed into a binary variable. For case-only analysis of certain prognostic characteristics, because the number of cases was limited in some categories, we dichotomized 25-OH vitamin D concentrations. All analyses were performed using SPSS 18.0 (IBM Corp., Somers, NY) with two-sided significance level of 0.05. The institutional review board of the University of Rochester retroactively approved these analyses with exempt status. Table 1 displays the results of the case-control analyses. Using a generalized linear model, mean 25-OH vitamin D levels were significantly lower in BC cases than in controls (cases = 32.7 ng/mL vs. controls = 37.4 ng/ mL; P = .02) after adjusting for age and date of blood draw. Results from logistic regression modeling show individuals who had deficient 25-OH vitamin D levels (\20 ng/mL) had significantly increased odds of having BC compared with noncancer controls (OR = 2.41, 95% CI = 1.30-4.48).
RESULTS
Mean 25-OH vitamin D levels by prognostic characteristics for the case-only series are shown in Table 2 . A Kolmogorov-Smirnov test confirmed that 25-OH vitamin D levels were normally distributed among the BC cases. Among the prognostic demographic variables, lower mean 25-OH vitamin D values were found for non-white (of 32 non-white participants, 24 were African American, five were Hispanic, and three were Asian) (nonwhite = 22.9 ng/mL vs. white = 34.9 ng/mL; P \ .01) and premenopausal (premenopausal = 29.2 ng/mL vs. postmenopausal = 34.0 ng/mL; P = .04) BC cases, and cases aged 53 and younger (B53 years old = 28.8 ng/mL vs. C66 years old = 36.1 ng/mL; P = 0.01). Among the prognostic tumor characteristics, lower mean 25-OH vitamin D levels were found for BC cases which were ER-(ER-= 28.1 ng/mL vs. ER? = 33.4 ng/mL; P = 0.04), triple negative (triple negative = 26.2 ng/mL vs. non-triple negative = 33.3 ng/mL; P = 0.02), and which had a basal-like molecular phenotype (basal-like = 24.2 ng/mL vs. Luminal A = 32.8 ng/mL; P = 0.04). Statistically borderline differences were found for PR status (PR-= 28.9 ng/mL vs. PR? = 33.4 ng/mL; P = 0.08), invasiveness (invasive = 32.0 ng/mL vs. in situ = 37.4 ng/ mL; P = 0.09), and Oncotype score (\18 = 31.5 ng/mL vs.[30 = 12.3 ng/mL; P = 0.07). No differences in mean 25-OH vitamin D levels were noted for HER2 status, tumor size, family history, or nodal involvement.
The OR and corresponding 95% CI by prognostic indicators for categorical 25 
DISCUSSION
In the case-control analysis, BC patients who had surgery at URMC between January 2009 and October 2010 had significantly lower mean 25-OH vitamin D levels than female noncancer patients who were treated at URMC during the same time period. Additionally, deficient serum levels of vitamin D (\20 ng/mL) were associated with a statistically significant 2.5-fold increase in the odds of breast cancer. In the case-series analysis, significantly lower mean 25-OH vitamin D levels were noted for poor prognostic indicators such as non-white race, premenopausal status, ER-expression, triple negative expression, and basal-like tumors. Similarly, deficient 25-OH vitamin D levels were associated with significantly increased odds for many of the same poor prognostic indicators. The strongest associations were observed in the subtypes of BC that have the highest mortality rates: triple negative histology and basal-like molecular phenotype.
The results of this study are in agreement with previous research that demonstrated the relationship between vitamin D deficiency, BC incidence, and more aggressive BC pathology. Numerous epidemiologic studies have examined the association between vitamin D levels and BC incidence. While results from those studies are inconsistent, reviews and meta-analyses indicate high 25-OH vitamin D levels protect against the development of breast cancer. 11, 12, 18 Only recently have researchers studied the association between serum vitamin D levels and prognostic indicators of breast cancer. Significant disparities exist by race for serum vitamin D levels in BC patients, with black BC patients having significantly lower vitamin D levels than white patients. 6 These poor prognostic factors result in increased BC mortality rates: Black BC patients have a 34% higher mortality rate than white BC patients, ER-patients have a significantly lower survival rate than ER? patients, and triple-negative patients have a 77% 5-year survival rate compared with 93% for non-triple negative patients. [20] [21] [22] Vitamin D also profoundly affects the phenotype of BC cells; the addition of vitamin D to BC cell cultures causes the reversion of certain epithelial features associated with poor prognosis in human breast cancers. 30 Several issues should be considered in interpreting the results of this study. Vitamin D levels were only assessed at a single time point and may not represent vitamin D levels over time. Nevertheless, some investigators have shown that 25-OH vitamin D levels remain relatively stable over several years. 31 While we were able to control for covariates such as age, race, laboratory used for testing, and date of blood draw, we could not control for body mass index (BMI). BMI is correlated with 25-OH vitamin D levels, although the correlation is modest, and failure to control for BMI may have confounded some of our results. 32 Additionally, the number of participants in certain BC subgroups (triple negative, ER?, basal-like tumors, Oncotype score C 18) was small, resulting in wide confidence intervals. Finally, because this is a cross-sectional study causality cannot be inferred and caution should be used when interpreting the results. Therefore, our results should be replicated in larger, prospective datasets that can further This study shows an association between low 25-OH vitamin D levels and poor prognostic indicators in BC patients, an association that is supported by a number of recent studies. 2, [6] [7] [8] The association was strongest for some of the worst prognostic indicators, such as triple negative status and basal-like breast tumors. Evidence from this study may explain why vitamin D deficient BC patients have decreased survival rates. Based on the strength of evidence from this study and other recent research, further investigation in this area is warranted. Clinical trials of vitamin D supplementation are needed to evaluate the efficacy of vitamin D both as a chemopreventive agent and as an adjuvant agent in combination with cancer treatment. For now, because of the importance of vitamin D in other health issues directly relevant to BC patients (bone loss, arthralgias, and falls), clinicians should screen for vitamin D deficiency and treat accordingly. 
